Items with tag "cancer"

News

The Nobel Assembly at Karolinska Institutet awards the 2018 Nobel Prize in Physiology or Medicine jointly to James P. Allison and Tasuku Honjo

1st October 2018 Cancer kills millions of people every year and is one of humanity’s greatest health challenges. By stimulating the inherent ability of our immune system to attack tumor cells …

Read more

Scientists unravel role of glutamine synthetase in the spread of cancer

Scientists have discovered an essential mechanism in the spread of cancer. A team led by professor Massimiliano Mazzone (VIB-KU Leuven) and professor Alessandra Castegna (University of Bari) has d…

Read more

iTeos Therapeutics Granted EUR 7.5 Million Non-Dilutive Funding by the Walloon Region

iTeos Therapeutics SA, announced that it has been granted EUR 7.5 million in non-dilutive funding to support the clinical development of its lead anti-cancer drug. The funding has been approved on…

Read more

BioWin launches two innovative projects to treat breast cancer and liver diseases

Two BioWin projects were launched a few weeks ago. The first of these, “TreatBest”, involves a consortium made up of Diagenode, IDDI, the Université Libre de Bruxelles (ULB), the Institut Jules Bo…

Read more

Celyad announces initiation of the SHRINK trial

SHRINK study to evaluate the synergetic effect of the concurrent administration of CYAD-01 (CAR-T NKG2D) with standard chemotherapy in patients suffering from metastatic colorectal cancer.

Read more

MDx Health's SelectMDx to be Distributed Across Middle East by IPS Genomix

MDx Health gains market access of the Middle East via partner IPS Genomix.

Read more

Biocartis and A*STAR's ETPL initiate development of breast cancer assay to guide therapy selection

Singapore's Agency for Science, Technology and Research will develop the new assay while Biocartis will be responsible for commercialisation.

Read more

MDxHealth Launches AssureMDx for Bladder Cancer Liquid Biopsy Test

Methylation specialist MDx Health brings its third assay to the market. The AssureMDx liquid biopsy assay is able to detect bladder cancer in a urine sample.

Read more

Biocartis launches CE-marked IVD test for lung cancer

Biocartis, an innovative molecular diagnostics company, today announced the CE-marking of the Idylla™ EGFR Mutation Test, as such achieving an important milestone in Biocartis' lung cancer menu. T…

Read more

MDxHealth Launches CE-Marked SelectMDx IVD PCR Kit and UrNCollect Device for prostate cancer

MDx Health has launched its new prostate cancer test. SelectMDx is designed to detect prostate cancer in urine samples, avoiding painful prostate biopsies when cancer is suspected.

Read more

Biocartis collaborates with MRC Technology in development of breast cancer liquid biopsy test

Together with MRC Technology, Biocartis has announced a collaboration for the development of a liquid biopsy test for hormone treatment-resistant breast cancer.

Read more

Scientists give tumor-fighting cells a boost in battling bone marrow cancer

Researchers from VIB-Ghent University and the VUB uncovered a new way to enhance the function of a specific type of immune cell that destroys tumors in multiple myeloma, a form of bone marrow canc…

Read more

PDC*Line Pharma awarded by board of international cancer experts

At the 8th edition of MATWIN’s annual international board meeting PDC*Line Pharma was awarded with the prize of Most Promising Project in the start-up category.

Read more

Biocartis launches CE-marked IVD NRAS test for colorectal cancer

To also serve geographies where BRAF testing is not reimbursed, Biocartis launches a new NRAS test next to their combined NRAS-BRAF assay.

Read more

A new unexpected key player in melanoma development identified

Identification and functional validation of proteins involved in tumorigenesis are essential steps toward advancing cancer precision medicine. In The Journal of Clinical Investigation researchers …

Read more

Kiadis Pharma files EMA marketing authorization for ATIR101™ in blood cancers

Kiadis Pharma asks permission to the EMA to bring its lead product to the market. ATIR101™ protects blood cancer patients receiving a stem cell transplant from vulnerability to infections and dise…

Read more

Characterising the profile of metastatic breast cancer for improved treatment

Researchers at the Jules Bordet Institute - Université libre de Bruxelles, VIB and KU Leuven recently published an important study offering a better understanding of the progression of breast canc…

Read more

argenx launches Phase II study for cutaneous T-cell lymphoma therapy

argenx starts a new phase II clinical trial with ARGX-110, a SIMPLE antibody targeting CD70. ARGX-110 will be evaluated as a monotherapy for relapsed/refractory cutaneous T-cell lymphoma (CTCL).

Read more

Liquid Biopsy is Cost-Effective for Biopsy Selection in prostate cancer

MDxHealth today announced BJU International published a study demonstrating that its SelectMDx for Prostate Cancer test can reduce overdiagnosis and overtreatment of men at risk of prostate cancer…

Read more

Biocartis opens doors in the US and appoints US General Manager

Biocartis opens doors in the US and appoints US General Manager Vishal Sikri to delegate outrol of Idylla in the states.

Read more

Licensing and collaboration deal for MDx Health and Ghent University

MDx Health and Ghent University have signed licensing and collaboration agreements for the development of biomarker visualisation technology in prostate and bladder cancer.

Read more

Kiadis Pediatric Investigation Plan concerning blood cancer approved by EMA

Kiadis Pharma N.V., a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that the Pedia…

Read more

Non-invasive colorectal cancer screening test

VIB and DNAlytics are proud to announce their partnership to develop a data-driven, high-performance and non-invasive Colorectal Cancer screening test, the ColonoKit.

Read more

Glucose starvation as a weapon in breast cancer

The Massimiliano Mazzone group (VIB-KU Leuven) has recently demonstrated that PP2A/B55α promotes the growth of colorectal cancer, by dephosphorylating PHD2 and modifying its enzymatic properties.

Read more

Biocartis receives grant for development of a fully automated MSI test

Belgian diagnostics producer receives grant from Flemish government to develop microsatellite instability (MSI) test in collaboration with VIB-KULeuven. Not only will the test offer prognosis esti…

Read more

Celyad obtains FDA approval to initiate the NKR-2 CAR-T cells THINK trial in the USA

Celyad announced that the U.S. FDA authorized the initiation of the THINK trial in the U.S. THINK evaluates NKR-2 CAR-T cells in seven indications, five solid cancers and two hematological maligna…

Read more

Researchers identify phosphorylation process vital to cancer growth

Scientists at VIB-KU Leuven have identified a new mechanism that impacts tumor growth. The typical lack of oxygen in tumors doesn’t only stimulate proliferation, but also offsets the important rol…

Read more

Mitochondrial lipids as potential targets in early onset Parkinson’s disease

A team of researchers led by Patrik Verstreken (VIB–KU Leuven) have identified an underlying mechanism in early onset Parkinson’s. Using flies, mice and patient cells, the team focused on cardioli…

Read more

MDxHealth Awarded US Department of Veterans Affairs Contract for ConfirmMDx Testing

MDxHealth today announced that it has been awarded a US Government Services Administration (GSA) supply contract to use ConfirmMDx for Prostate Cancer within the Department of Veterans Affairs (VA…

Read more

Scientists use tumor-derived dendritic cells to slow tumor growth

​In the human body, so-called dendritic cells are responsible for activating our immune system. While researchers previously believed that tumors could repress these dendritic cells – blocking an …

Read more

OCTIMET Oncology NV secures over EUR 11 million to develop its highly selective MET kinase inhibitors

Octimet Oncology announced today that it has completed its series A investment round. The cancer start-up was able to secure €11.3 million from an investment syndicate led by V-Bio Ventures and Fu…

Read more

MDx Health ConfirMDx test covered by new insurance group

MDxHealth Announces Horizon Blue Cross Blue Shield of New Jersey Issues Positive Coverage Policy on ConfirmMDx. The decision provides access to more than 3.8 million members.

Read more

Medulloblastoma orphan drug designation for Oncurious

Oncurious, an emerging oncology company focused on the development of innovative orphan drugs for the treatment of pediatric tumors, announces that the European Commission has confirmed the orphan…

Read more

Watson is here to cure cancer

The cooperation between Pfizer and IBM concerning Watson, an artificial intelligence system, was announced on the Forbes Healthcare Summit following a pilot project during the past year and a half…

Read more

Ontoforce wins European Digital Health prize

Last week, ONTOFORCE, claimed the first spot in the ‘Digital Health’ category at the EIT Health Summit in Barcelona, for which it receives €25,000. In addition, ONTOFORCE came third in the public …

Read more

Finnish start-up brings cancer care in digital format

Digital technology keeps on finding its way into the healthcare space. Finnish start-up Noona healthcare has set its eyes on cancer care, and provides a mobile service for the personal follow-up o…

Read more

Celyad about to start second cancer immunotherapy clinical trial

Celyad will soon initiate the THINK clinical trial. THINK is the second clinical trial of its NKR-2 product candidate, a CAR-T cell therapy using NKG2D ligands as a target, to evaluate safety and …

Read more

WHITE PAPER ON CANCER IMMUNOTHERAPY - CALL OPEN

BioVox is currently developing a White Paper on Cancer Immunotherapy, showcasing innovators and world leaders in this exciting field. Are you an innovative player and do you want to promote y…

Read more

Increase oxygen to fight cancer

​The lack of oxygen in tumor cells changes the cells’ gene expression, thereby contributing to the growth of cancer. This is the main conclusion of a research project led by professor Diether Lamb…

Read more

Celyad cuts deal with Ono Pharmaceutical on immunotherapy treatment

Japan's Ono Pharmaceutical will license a cancer treatment of Celyad. The collaboration is very welcome, as two weeks ago, the Walloon company had to share disappointing results of C-Cure, a stem …

Read more

VIB-KULeuven/ULB research team discover new cancer target

In a collaborative effort, researchers of the labs of Jean-Christophe Marine (VIB-KULeuven) and Cédric Blanpain (ULB) have discovered an intriguing novel target for cancer therapy. NEAT1, a non-co…

Read more

CDK4/CDK6 inhibitors show great promise for breast cancer treatment

Abstracts released Wednesday ahead of next month's American Society of Clinical Oncology meeting showed strong survival and response rate data for cyclin dependent kinase 4 (CDK4) and CDK6 inhibit…

Read more

Europe approves Opdivo-Yervoy immuno combination for melanoma

Bristol-Myers Squibb Co. (NYSE:BMY) said the European Commission approved Opdivo nivolumab in combination with Yervoy ipilimumab to treat advanced melanoma in adults independent of BRAF mutation s…

Read more

NewLink's IMPRESS results disappoint

NewLink Genetics Corp. (NASDAQ:NLNK) sank $5.50 (33%) to $11 in early after-hours trading Monday after it said HyperAcute Pancreas algenpantucel-L missed the primary overall survival endpoint in t…

Read more

Argen-X lands AbbVie

Argen-X starts a collaboration with the global biopharmaceutical company AbbVie to develop and commercialize its novel immuno-oncology drug candidate, ARGX-115. ARGX-115 is  a preclinical-stage hu…

Read more

Alphabodies for cancer treatment by Complix-Merck collaboration

The Hasselt-based company Complix entered into a collaboration with Merck (MSD), for development of Alphabodies™. Alphabodies™ are synthetic cell-penetrating antibodies (CPABs) for the treatment o…

Read more

Biocartis - Merck partnership for colorectal cancer diagnostics

Biocartis closed a deal with Merck KGaA (Merck) for the development and commercialization of a new liquid biopsy RAS biomarker test for patients with metastatic colorectal cancer (mCRC). A patient…

Read more

BMS and Oncodesign enter into partnership: new drug candidates ahead!

Today, Oncodesign announced a new strategic collaboration, the largest of the company to date. The French drug developer will provide its services to pharma titan Bristol-Myers Squibb in the searc…

Read more

Faster cancer diagnosis: new Idylla products

Biocartis launched two new products for cancer diagnosis to use with its molecular diagnostics platform Idylla™; a liquid biopsy test and a tissue biopsy test.  The first product, a ctBRAF Mut…

Read more

IBA: Major breakthrough for proton therapy

With profits of 112%, IBA is one of the star companies of 2015. More and more hospitals acknowledge the enormous benefits of proton therapy to fight cancer. You do not often encounter a CEO th…

Read more

Fast and easy tumor detection with liquid biopsy

VITO and the Antwerp University Hospital (UZA) recently joined forces with 3 Flemish companies, Biocartis, RIC and Pharmafluidics for the project ‘Early Diagnosis by Easy Sampling’. The consortium…

Read more

Ghent Universitary Hospital starts leukemia immunotherapy trial

The Ghent Universitary Hospital will start on November 20 with a new clinical trial for treatment of leukemia; only seven centers in Europe participate in this scientific study. The treatment conc…

Read more

GlycoCirrho test predicts liver cancer

Researchers at the UZ Ghent have discovered that the GlycoCirrhoTest for the early detection of cirrhosis also accurately predicts the risk for the development of liver cancer. Their results are p…

Read more

€1.4 million for liquid biopsy to detect cancer

The IWT (Flemish Agency for Innovation by Science and Technology) granted 1,4 million euros to Biocartis to support the development of a liquid biopsy diagnostic test for melanoma and colorectal c…

Read more

Allogeneic CAR T-cells patented by Celyad

Celyad obtained a patent relating to allogeneic Chimeric Antigen Receptor (CAR) T-cells. CAR T-cells are T-cells, which are engineered to better recognize and fight cancerous cells. The use of all…

Read more

New test to diagnose prostate cancer with urine sample

MDxHealth (Herstal) announced today the launch of a new non-invasive, “liquid biopsy”, diagnostic test for prostate cancer using a urine sample. Initially, the test, named SelectMDx, is offered in…

Read more

Dutch company acquired by MDxHealth

The Dutch biotech company NovioGendix is acquired by the Belgian company MDxHealth. MDxHealth will pay $ 8.8 million (€ 7.8 million) for the Nijmegen-based company. NovioGendix is a spin-off of th…

Read more

Urine HPV screening

HPV is the most common sexually transmitted infection (1). While most infections are subclinical, two virus serotypes are known to be carcinogenic. The lack of symptoms and the discomfort associat…

Read more

Non-invasive test for diagnosis bladder cancer

Bladder cancer is the fifth most common cancer in the western world.  MDxHealth developed a urine-based bladder cancer test for patients with hematuria (blood in urine). The test will provide phys…

Read more

Biogazelle receives 1 million euro to develop cancer therapy

Biogazelle today announced that it has received €1.1M in funding from the agency for Innovation by Science and Technology (IWT) in Flanders to leverage its cancer therapy development program, focu…

Read more

Prof. Carmeliet as Chief Scientific Strategy Advisor at Oncurious

Oncurious NV, an oncology company focused on the development of innovative medicines for the treatment of pediatric tumors, today announces the appointment of Prof Dr Peter Carmeliet as its Chief …

Read more

“Give Life a Chance”: new research fund for neuroendocrine tumors

The University of Hasselt, the Jessa Hospital and the East Limburg Hospital will conduct research on neuroendocrine tumors (NET), a rare and aggressive form of cancer, with help from “Give Life a …

Read more

More screening options for breast and ovarian cancers

Multiplicom releases two new kits for the screening of hereditary breast and ovarian cancer. In addition to the tests for BRCA1 and BRCA2 released in 2012, Multiplicom’s novel assays include a com…

Read more

MiDiagnostics develops disposable chip for blood self-testing

MiDiagnostics is a new startup that will make disposable chips to test your own blood and saliva. Only 15 minutes after the test, you will be able to read on your smartphone whether you have to ta…

Read more

arGEN-x receives €1.5 million for enhancement of therapeutic antibodies

In early May 2015, arGEN-X N.V. (ARGX) received a €1.5 million grant from the Flemish IWT (the government agency for Innovation by Science and Technology). arGEN-X creates novel therapeutic antibo…

Read more

Biocartis to present BRAF liquid biopsy data at ASCO

Biocartis (BCART), will today present liquid biopsy data from the BRAF mutation study at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The study, in collaboration wit…

Read more

Genticel focuses on curing HPV before it turns into cervical cancer

70% of cervical cancer cases are caused by human papillomavirus (HPV) and the traditional HPV vaccines are only useful to prevent, not to treat the infection. Genticel (GTCL) is developing a solut…

Read more

There’s hope for patients with advanced melanoma

In patients with advanced skin cancer, the drug Opdivo nearly doubles the chances of survival. The European Medicines Agency has issued a positive opinion to bring it to market, though it has a hi…

Read more

Congrats to Biocartis!

The Mechelen-based biotech company Biocartis starts its IPO adventure. The demand for shares was 6,5 times higher than the offer. Biocartis gathered 100 million euros with an offer of 8,7 million …

Read more

ThromboGenics and VIB found oncology company

Oncurious is a new oncology company that will perform clinical trials for the development of TB-403. This compound is a new promising agent for the treatment of brain tumors in children. Alongs…

Read more

Belgian scientists in Nature with cancer breakthrough

Scientists Peter Carmeliet and Sarah-Maria Fendt (KU Leuven/VIB) published in the prestigious Nature journal on their fundamental breakthrough in cancer research. They found a new way to prevent b…

Read more

Insights

Saving lives through fundamental research: James Allison wins Dr. Paul Janssen Award 2018

Saving lives through fundamental research: James Allison wins Dr. Paul Janssen Award 2018

Dr. James Allison has dedicated his career to improving our fundamental understanding of how the adaptive immune system works. Much of what you will find on T cells in today’s immunology textbooks…

Read more

Damya Laoui at the forefront of cancer immunotherapy

Damya Laoui at the forefront of cancer immunotherapy

Photo copyright: VUB / Thierry Geenen Last year, Damya Laoui received the prestigious American MIT-prize for young innovators under 35 for her research on cancer immunotherapy.  She is current…

Read more

Two genes work together to trigger childhood leukemia

Two genes work together to trigger childhood leukemia

Two known cancer-causing genes, HOXA9 and JAK3/STAT5, are cooperating to trigger acute lymphoblastic leukemia, a common form of childhood cancer. Although both genes were already known to play a s…

Read more

The controversy around sugar and cancer

The controversy around sugar and cancer

In a recent article published in Nature Communications (1) by a group of scientists led by Belgian professor Johan Thevelein from VIB-KU Leuven, it was revealed that sugar breakdown activates Ras …

Read more

Celyad: CAR-T cells with natural killer skills fight cancer

Celyad: CAR-T cells with natural killer skills fight cancer

Celyad, based in Mont-Saint-Guibert (Belgium), was originally established in 2004 as a company active in regenerative cell therapy. However, two years ago, Celyad decided to move into immuno-oncol…

Read more

Vaccinating against cancer with dendritic cells

Vaccinating against cancer with dendritic cells

Founded as a spin-off from the French Blood Bank, PDC*line Pharma is focused on developing immunotherapeutic vaccines. These vaccines contain their proprietary and unique plasmacytoid dendritic ce…

Read more

ImmunXperts: your partner for in vitro assays in cancer immunotherapy

ImmunXperts: your partner for in vitro assays in cancer immunotherapy

Although immunotherapy in cancer is booming, it isn’t by any measure an easy field to navigate. Many oncology ventures willing to explore this new terrain find themselves quickly lost in an array …

Read more

Diagnosed with lung cancer

Diagnosed with lung cancer

A patient diagnosed with lung cancer should brace for the worst. Prognosis is often very disappointing. While in many cancers early diagnosis and treatment is key, lung cancer patients experience …

Read more

Tackling untreatable cancers in children

Tackling untreatable cancers in children

Bram De Wilde is a pediatric hemato-oncologist at the University Hospital in Ghent. He is one of the keynote speakers in the afternoon session at the ‘Kankercongres’ in Ghent, October 21. Kankerco…

Read more

Very promising cancer treatment: RNAi immunotherapy

Very promising cancer treatment: RNAi immunotherapy

RXi Pharmaceuticals was co-founded by Craig Mello, PhD, the co-recipient of the 2006 Nobel Prize in Medicine for the discovery of RNA interference (RNAi). To advance the use of RNAi into therapeut…

Read more

Dendritic cells boosted with mRNA form promising cancer immunotherapy

Dendritic cells boosted with mRNA form promising cancer immunotherapy

With its expertise in mRNA production and knowledge of the biology of dendritic cells, eTheRNA has developed TriMix, a new mRNA technology platform. TriMix consists of a cocktail of three mRNAs, w…

Read more

IDO 1: a promising new target for immunotherapy

IDO 1: a promising new target for immunotherapy

iTeos Therapeutics started in 2012 as a spin-off from the Ludwig Institute for Cancer Research (LICR), one of the top three cancer institutes in the world, and the UCL. In 2014, they licensed righ…

Read more

Immunotherapy: a paradigm shift in cancer treatment

Immunotherapy: a paradigm shift in cancer treatment

An excerpt from the BioVox White paper on Cancer Immunotherapy.

Read more

Arming cells with a cancer vaccine

Arming cells with a cancer vaccine

In immunotherapy, the patient’s own immune system is activated to fight cancer cells. Such strategies have been pursued for a few decades and are currently seeing their first commercial applicatio…

Read more

Huge steps forward in VIB skin cancer research

Huge steps forward in VIB skin cancer research

When it comes to finding a cure for melanoma skin cancer, major strides are being taken as we speak. One of the driving forces behind this great work is Chris Marine (VIB/KU Leuven). His team has …

Read more

CAR-T: The T-cell training program to fight cancer

CAR-T: The T-cell training program to fight cancer

Immunotherapy is by far the hottest topic in the cancer research world. One immune approach in particular has created high expectations: CAR-T. This method of reprogramming T-cells has shown impre…

Read more

All in on cancer immunotherapy

All in on cancer immunotherapy

Founded in 2011, iTeos Therapeutics began its activities at the end of 2012. Active in the field of cancer immunotherapy, the company develops innovative drugs by focusing on the tumor microenviro…

Read more

Precision oncology: shaping a patient-centric approach

Precision oncology: shaping a patient-centric approach

OncoDNA was founded only three years ago in Gosselies. Its focus: help the oncologist follow the evolution of a patient’s cancer, collect relevant clinical data on this cancer and create a network…

Read more

Anti-cancer vaccine around the corner

Anti-cancer vaccine around the corner

​Researchers in the group of Prof. Dr. Peter Vandenabeele (VIB/UGent) show that killed tumour cells can serve as a potent vaccine that stimulates the immune system to prevent the outgrowth of canc…

Read more

Sammson gene causes melanoma

Sammson gene causes melanoma

In collaboration with big N2N researchers from UGent, VIB scientists from KU Leuven have revealed a remarkable link between malignant melanoma and a non-coding RNA gene called SAMMSON. The SAMMSON…

Read more

Skin on skin: Melanoma research at VIB

Skin on skin: Melanoma research at VIB

Melanoma is a particularly nasty type of skin cancer. It progresses and spreads very quickly, and in many cases it is resistant to chemotherapy. Currently, two VIB research groups are investigatin…

Read more

Preventing cervical cancer: vaccinating or freezing?

Preventing cervical cancer: vaccinating or freezing?

The group of human papillomaviruses has over 100 types, of which at least thirteen can cause cancer. The virus is present in people all over the world and is mainly spread through sexual contact. …

Read more

The Fournier-Majoie Foundation: guiding cancer research to clinical application

The Fournier-Majoie Foundation: guiding cancer research to clinical application

At 77 years of age, Bernard Majoie is as active as ever. As founder of the Fournier-Majoie Foundation, he dedicates his time to the battle against cancer. His philanthropic foundation provides fun…

Read more

A perspective of the future - Towards a cure for cancer and much more

A perspective of the future - Towards a cure for cancer and much more

‘Within 10 years we will be able to cure cancer’. A bold statement? Paul Stoffels (CSO J&J) doesn’t think so. He is a believer. He is also persistent, passionate, likes to be challenged and cha…

Read more

A look across the border at cancer research and drug discovery

A look across the border at cancer research and drug discovery

Jan Hoflack is chief scientific officer at the Dijon-based Oncodesign, a  drug discovery company and oncology service provider. Hoflack joined Oncodesign in 2009 and introduced the Nanocyclix drug…

Read more

Nuclear technology saves lives, especially in Belgium!

Nuclear technology saves lives, especially in Belgium!

Nuclear energy has become a part of our every day lives, but not solely for electricity production. Over the last century, nuclear technology has become increasingly important in health care. It a…

Read more

Engineered immune cells to fight cancer

Engineered immune cells to fight cancer

Our own immune T-cells can be one of the best defense lines against cancer. Walloon biopharmaceutical company Celyad is using an innovative approach to harness a patient's own immune system to dir…

Read more

A user experience of Idylla™, the mini-lab

A user experience of Idylla™, the mini-lab

Idylla™, Biocartis’ fully automated molecular diagnostics system was launched in September 2014. Since then, over 100 units have been sold. We asked the very first customer, Prof. dr. Bart Neyns t…

Read more

Nanobodies®: small magical molecules for big difficult diseases

Nanobodies®: small magical molecules for big difficult diseases

One of Belgium’s established biotech companies, Ablynx, has developed an innovative platform to produce small therapeutic proteins, called Nanobodies. These Nanobodies are being developed for the …

Read more

Starving cancer with a fat free diet

Starving cancer with a fat free diet

During the development of cancer, our metabolism is hijacked, and new blood vessels are formed to provide nutrients to the growing tumor. Scientists from VIB and KU Leuven are working on how to st…

Read more

VoltionRx detects colon cancer with a drop of blood

VoltionRx detects colon cancer with a drop of blood

Belgian Volition – a subsidiary of Volition Rx – is a life sciences company located in Namur (Belgium) focused on developing blood-based diagnostic tests for a broad range of cancer types and othe…

Read more

New in Belgium: a state-of-the-art integrated care cancer center

New in Belgium: a state-of-the-art integrated care cancer center

The University Hospital Center in Liège is expanding. The new comprehensive cancer center will be ready in 2018. The center focuses on high quality integrated care, and a large part of the buildin…

Read more

Stem Cell Therapy is big in Wallonia

Stem Cell Therapy is big in Wallonia

What do Bone Therapeutics, Cardio3 Biosciences and Imcyse all have in common? They focus on stem cell therapy and are all linked to the Laboratory of Cell and Gene Therapy (LTCG) led by Yves Begui…

Read more

Frederic de Sauvage in San Francisco – Belgian scientist living abroad

Frederic de Sauvage in San Francisco – Belgian scientist living abroad

I live in the San Francisco Bay Area and work for Genentech, the first biotechnology company ever started (in 1976). I did my Ph.D. at the Catholic University of Louvain (UCL), but decided early o…

Read more

Cancer immunotherapy: the ultimate ally in the tumor war

Cancer immunotherapy: the ultimate ally in the tumor war

Can immunotherapy cure cancer? Fighting cancer with our own immune system. It sounds promising. At the end of the 1800s, the controversial Dr. William Coley  suggested that infections fuel the imm…

Read more

VC Views

Grail: A billion-dollar gamble?

Grail: A billion-dollar gamble?

Grail has vowed to change the field of cancer diagnostics via simple blood tests and ctDNA analysis. Their Big Data approach, in which the company will build an atlas of DNA found in the blood, co…

Read more

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

Itera Life Science UGent Janssen GSK KU Leuven V-Bio Ventures Turnstone XpandInnovation Flanders.bio Biowin

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.